Skip to main content
BEAM logo

Beam Therapeutics Inc. (BEAM) Stock: Price, Forecast & Analyst Target

Beam Therapeutics Inc. (BEAM) — MoonshotScore 28/100 (Weak band), calculated Nov 18, 2026. Price $20.94 (-0.33%), as of the Nov 19, 2026 trading session; market cap $2.17B.

Educational signal · not a buy or sell recommendation · How to read this

$20.94 −$0.07 (-0.33%) Market Cap $2.17B

Beam Therapeutics Inc. · BEAM · NASDAQ

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines for serious diseases in the United States.

Price as of Nov 19, 2026

Key Statistics

28 of 100

MoonshotScore v2 · Beam Therapeutics (BEAM)

Weak
Business Quality Thin (26)
Financial Safety Okay (52)
Valuation Full (45)
Growth Durability Growing (79)
Momentum Quiet (51)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but weak quality and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Quiet.

  • EPS beat 1 of the last 4 reports
  • Altman Z 2.63 · Piotroski F 2
  • ROE -11.3% · ROA -19.0% · current ratio 13.01

Holding back: weak fundamentals

Helping: durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BEAM (57 recorded, newest six shown)
RecordedScoreBand
28Weak
28Weak
28Weak
28Weak
28Weak
28Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$20.94
Change on the day-0.33%
52-week range$20.23 – $38.26
Market capitalisation$2.17B
Price / earnings (trailing)-5.80
Shares traded on the day4.21M

Price & events

Other perspectives

Council score for Beam Therapeutics (BEAM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Neutral
Growth Durability Moderate
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Beam Therapeutics (BEAM), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Beam Therapeutics Inc. (BEAM) is listed on NASDAQ. It employs 540 people and is led by John Evans. The market values it at $2.17B.

2 · Latest results

What do the latest results show for Beam Therapeutics (BEAM)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$10M-$113M-$1.10 (diluted)
Q4 FY2025$114M$244M$2.33 (diluted)
Q1 FY2026$32M-$94M-$0.91 (diluted)
Q2 FY2026$490,000-$123M-$1.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Beam Therapeutics (BEAM)?

Short answer

The MoonshotScore pillars rate durable growth as strengths. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z 2.63 · Piotroski F 2. Trailing ratios: ROE -11.3% · ROA -19.0% · current ratio 13.01.

Data-derived red flags

  • Negative return on equity (-11.3%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Beam Therapeutics (BEAM)?

Short answer · as of

Current published price targets run low $79.00 · high $80.00 · consensus $79.50 · median $79.50 against a quoted price of $20.94 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Beam Therapeutics compare with its peers?

Short answer

Beam Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$61.99 Nov 18, 2026$1.79B98 5-pillar Nov 18, 2026
Aurinia Pharmaceuticals Inc. (AUPH) Same industry, near in market value$15.13 Nov 18, 2026$2.03B97 5-pillar Nov 18, 2026
ADMA Biologics, Inc. (ADMA) Same industry, near in market value$13.56 Nov 18, 2026$3.01B97 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$14.10 Nov 18, 2026$1.54B97 5-pillar Nov 18, 2026
Harmony Biosciences Holdings, Inc. (HRMY) Same industry, near in market value$33.11 Nov 18, 2026$1.94B96 5-pillar Nov 18, 2026
Vericel Corporation (VCEL) Same industry, near in market value$58.26 Nov 19, 2026$2.97B95 5-pillar Nov 18, 2026
Veracyte, Inc. (VCYT) Same industry, near in market value$25.57 Nov 18, 2026$2.06B89 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$47.40 Nov 19, 2026$1.41B76 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.20 Nov 19, 2026$3.37B66 5-pillar Nov 18, 2026
Trevi Therapeutics, Inc. (TRVI) Same industry, near in market value$13.72 Nov 19, 2026$1.96B63 5-pillar Nov 18, 2026
SELLAS Life Sciences Group, Inc. (SLS) Same industry, near in market value$14.86 Nov 19, 2026$3.03B63 5-pillar Nov 18, 2026
Beam Therapeutics (BEAM) — this page$20.94$2.17B28

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$79.00 – $80.00
Consensus target
$79.50
Median target
$79.50

Consensus record · Captured .

Measured against a quoted price of $20.94 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 16, 2026

Transactions
30
Identified insiders
11
Purchases
0
Sales
11
Other transactions
19

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BEAM in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20261.66%$288.64MAdded +15.3% shares
Duquesne Family OfficeStanley DruckenmillerQ3 20260.38%$17.11MAdded +355.5% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Beam Therapeutics (BEAM)?

Read these with our analysis →

Beam Therapeutics Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the BEAM research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for BEAM?

BEAM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is BEAM a good stock to buy?

Stock Expert AI does not rate BEAM buy, sell or hold. Beam Therapeutics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the BEAM stock price today?

The last price recorded for Beam Therapeutics Inc. (BEAM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BEAM price target?

The analyst consensus price target for Beam Therapeutics Inc. (BEAM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What revenue streams does Beam Therapeutics Inc. have in healthcare?

As a clinical-stage biotechnology company, Beam Therapeutics Inc. currently does not have commercialized products generating direct product sales revenue. Its primary 'revenue' streams, characteristic of companies in this development phase, typically come from strategic collaborations and licensing agreements.

What are the key factors to evaluate for BEAM?

Beam Therapeutics Inc. (BEAM) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Strategic Alliances: The company has established significant research and clinical collaborations with entities such as Pfizer Inc., Verve Therapeutics, Inc., and Boston Children's Hospital, underscoring its strategy to leverage external expertise and resources for pipeline development. Not financial advice.

How frequently does BEAM data refresh on this page?

BEAM's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven BEAM's recent stock price performance?

Beam Therapeutics Inc. (BEAM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary base editing technology offers a differentiated approach to precision genetic medicine. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider BEAM overvalued or undervalued right now?

Beam Therapeutics Inc. (BEAM) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 12 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.